Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
Public ClinicalTrials.gov record NCT03074513. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors
Study identification
- NCT ID
- NCT03074513
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 133 participants
Conditions and interventions
Conditions
- Appendix Adenocarcinoma
- Human Papillomavirus-Related Anal Squamous Cell Carcinoma
- Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
- Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
- Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
- Neuroendocrine Carcinoma
- Pancreatic Neuroendocrine Tumor
- Recurrent Merkel Cell Carcinoma
- Recurrent Nasopharynx Carcinoma
- Recurrent Peritoneal Malignant Mesothelioma
- Recurrent Pleural Malignant Mesothelioma
- Stage III Merkel Cell Carcinoma AJCC v7
- Stage III Nasopharyngeal Carcinoma AJCC v7
- Stage III Pleural Malignant Mesothelioma AJCC v7
- Stage IV Merkel Cell Carcinoma AJCC v7
- Stage IV Nasopharyngeal Carcinoma AJCC v7
- Stage IV Pleural Malignant Mesothelioma AJCC v7
- Stage IVA Nasopharyngeal Carcinoma AJCC v7
- Stage IVB Nasopharyngeal Carcinoma AJCC v7
- Stage IVC Nasopharyngeal Carcinoma AJCC v7
- Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
- Atezolizumab Drug
- Bevacizumab Biological
- Laboratory Biomarker Analysis Other
- Pharmacological Study Other
Drug · Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2, 2017
- Primary completion
- Sep 29, 2027
- Completion
- Sep 29, 2027
- Last update posted
- Mar 10, 2026
2017 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03074513, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03074513 live on ClinicalTrials.gov.